

# Pedro Brites

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8020883/publications.pdf>

Version: 2024-02-01

37  
papers

2,121  
citations

361413

20  
h-index

361022

35  
g-index

38  
all docs

38  
docs citations

38  
times ranked

2504  
citing authors

#	ARTICLE	IF	CITATIONS
1	Variants in ADD1 cause intellectual disability, corpus callosum dysgenesis, and ventriculomegaly in humans. <i>Genetics in Medicine</i> , 2022, 24, 319-331.	2.4	6
2	Plasmalogens regulate the AKT-ULK1 signaling pathway to control the position of the axon initial segment. <i>Progress in Neurobiology</i> , 2021, 205, 102123.	5.7	10
3	Profilin 1 delivery tunes cytoskeletal dynamics toward CNS axon regeneration. <i>Journal of Clinical Investigation</i> , 2020, 130, 2024-2040.	8.2	30
4	Leukodystrophy caused by plasmalogen deficiency rescued by glyceryl 1-oleoyl ether treatment. <i>Brain Pathology</i> , 2019, 29, 622-639.	4.1	30
5	Autonomous Purkinje cell axonal dystrophy causes ataxia in peroxisomal multifunctional protein-2 deficiency. <i>Brain Pathology</i> , 2018, 28, 631-643.	4.1	10
6	Mitochondrial disruption in peroxisome deficient cells is hepatocyte selective but is not mediated by common hepatic peroxisomal metabolites. <i>Mitochondrion</i> , 2018, 39, 51-59.	3.4	26
7	The Dyslexia-susceptibility Protein KIAA0319 Inhibits Axon Growth Through Smad2 Signaling. <i>Cerebral Cortex</i> , 2017, 27, 1732-1747.	2.9	29
8	Early-onset Purkinje cell dysfunction underlies cerebellar ataxia in peroxisomal multifunctional protein-2 deficiency. <i>Neurobiology of Disease</i> , 2016, 94, 157-168.	4.4	15
9	Axonal pathology in Krabbe's disease: The cytoskeleton as an emerging therapeutic target. <i>Journal of Neuroscience Research</i> , 2016, 94, 1037-1041.	2.9	10
10	The Actin-Binding Protein F-Actin-Adducin Is Required for Maintaining Axon Diameter. <i>Cell Reports</i> , 2016, 15, 490-498.	6.4	95
11	Myelin Lipids Inhibit Axon Regeneration Following Spinal Cord Injury: a Novel Perspective for Therapy. <i>Molecular Neurobiology</i> , 2016, 53, 1052-1064.	4.0	23
12	Plasmalogens and fatty alcohols in rhizomelic chondrodysplasia punctata and Sjögren-Larsson syndrome. <i>Journal of Inherited Metabolic Disease</i> , 2015, 38, 111-121.	3.6	25
13	Plasmalogen phospholipids protect internodal myelin from oxidative damage. <i>Free Radical Biology and Medicine</i> , 2015, 84, 296-310.	2.9	65
14	Poly(trimethylene carbonate-co- $\epsilon$ -caprolactone) Promotes Axonal Growth. <i>PLoS ONE</i> , 2014, 9, e88593.	2.5	24
15	Morphometric analysis of sciatic nerve images: A directional gradient approach. , 2014, , .		0
16	A PEX7-Centered Perspective on the Peroxisomal Targeting Signal Type 2-Mediated Protein Import Pathway. <i>Molecular and Cellular Biology</i> , 2014, 34, 2917-2928.	2.3	34
17	Early axonal loss accompanied by impaired endocytosis, abnormal axonal transport, and decreased microtubule stability occur in the model of Krabbe's disease. <i>Neurobiology of Disease</i> , 2014, 66, 92-103.	4.4	55
18	Peripheral nervous system plasmalogens regulate Schwann cell differentiation and myelination. <i>Journal of Clinical Investigation</i> , 2014, 124, 2560-2570.	8.2	103

#	ARTICLE	IF	CITATIONS
19	Advances and Pitfalls of Cell Therapy in Metabolic Leukodystrophies. <i>Cell Transplantation</i> , 2013, 22, 189-204.	2.5	17
20	The importance of ether-phospholipids: A view from the perspective of mouse models. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2012, 1822, 1501-1508.	3.8	65
21	Comparative profiling of the peroxisomal proteome of wildtype and Pex7 knockout mice by quantitative mass spectrometry. <i>International Journal of Mass Spectrometry</i> , 2012, 312, 30-40.	1.5	21
22	Alkyl-Glycerol Rescues Plasmalogen Levels and Pathology of Ether-Phospholipid Deficient Mice. <i>PLoS ONE</i> , 2011, 6, e28539.	2.5	104
23	Biosynthesis of ether-phospholipids including plasmalogens, peroxisomes and human disease: new insights into an old problem. <i>Clinical Lipidology</i> , 2010, 5, 379-386.	0.4	21
24	Peroxisomes, lipid metabolism and lipotoxicity. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2010, 1801, 272-280.	2.4	135
25	Ataxia with loss of Purkinje cells in a mouse model for Refsum disease. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2008, 105, 17712-17717.	7.1	108
26	Plasmalogens participate in very-long-chain fatty acid-induced pathology. <i>Brain</i> , 2008, 132, 482-492.	7.6	89
27	Organization and integration of biomedical knowledge with concept maps for key peroxisomal pathways. <i>Bioinformatics</i> , 2008, 24, i21-i27.	4.1	7
28	The mouse as a model to understand peroxisomal biogenesis and its disorders. <i>Drug Discovery Today: Disease Models</i> , 2004, 1, 193-198.	1.2	3
29	Functions and biosynthesis of plasmalogens in health and disease. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2004, 1636, 219-231.	2.4	329
30	Identification of PEX7 as the Second Gene Involved in Refsum Disease. <i>American Journal of Human Genetics</i> , 2003, 72, 471-477.	6.2	151
31	Impaired neuronal migration and endochondral ossification in Pex7 knockout mice: a model for rhizomelic chondrodysplasia punctata. <i>Human Molecular Genetics</i> , 2003, 12, 2255-2267.	2.9	97
32	Identification of PEX7 as the Second Gene Involved in Refsum Disease. <i>Advances in Experimental Medicine and Biology</i> , 2003, 544, 69-70.	1.6	13
33	Mutational Spectrum in the PEX7 Gene and Functional Analysis of Mutant Alleles in 78 Patients with Rhizomelic Chondrodysplasia Punctata Type 1. <i>American Journal of Human Genetics</i> , 2002, 70, 612-624.	6.2	92
34	Molecular basis of rhizomelic chondrodysplasia punctata type I: High frequency of the Leu-292 Stop mutation in 38 patients. <i>Journal of Inherited Metabolic Disease</i> , 1998, 21, 306-308.	3.6	10
35	Rhizomelic chondrodysplasia punctata is a peroxisomal protein targeting disease caused by a non-functional PTS2 receptor. <i>Nature Genetics</i> , 1997, 15, 377-380.	21.4	260
36	Mutational Analysis of an X-Linked Adrenoleukodystrophy (ALD) Patient with Detectable ALD Protein. <i>Annals of the New York Academy of Sciences</i> , 1996, 804, 756-759.	3.8	1

#	ARTICLE	IF	CITATIONS
37	Pleiotropic effects of fenretinide in neuroblastoma cell lines and multicellular tumor spheroids. International Journal of Oncology, 0, , .	3.3	8